Goldman Sachs’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-57,207
| Closed | -$1.09M | – | 6727 |
|
|
2022
Q1 | $1.09M | Buy |
57,207
+50,292
| +727% | +$791K | ﹤0.01% | 4750 |
|
|
2021
Q4 | $123K | Sell |
6,915
-2,962
| -30% | -$88.8K | ﹤0.01% | 6078 |
|
|
2021
Q3 | $366K | Buy |
9,877
+4,258
| +76% | +$189K | ﹤0.01% | 5381 |
|
|
2021
Q2 | $334K | Sell |
5,619
-31,546
| -85% | -$1.91M | ﹤0.01% | 5456 |
|
|
2021
Q1 | $2.49M | Buy |
37,165
+14,149
| +61% | +$1.11M | ﹤0.01% | 3770 |
|
|
2020
Q4 | $1.39M | Sell |
23,016
-18,819
| -45% | -$1.28M | ﹤0.01% | 3980 |
|
|
2020
Q3 | $3.31M | Buy |
41,835
+32,153
| +332% | +$2.56M | ﹤0.01% | 3219 |
|
|
2020
Q2 | $605K | Buy |
9,682
+155
| +2% | +$9.02K | ﹤0.01% | 4267 |
|
|
2020
Q1 | $505K | Sell |
9,527
-9,387
| -50% | -$931K | ﹤0.01% | 4210 |
|
|
2019
Q4 | $2.29M | Buy |
18,914
+12,382
| +190% | +$1.78M | ﹤0.01% | 3543 |
|
|
2019
Q3 | $1.19M | Sell |
6,532
-3,226
| -33% | -$455K | ﹤0.01% | 3917 |
|
|
2019
Q2 | $1.27M | Sell |
9,758
-4,332
| -31% | -$777K | ﹤0.01% | 3823 |
|
|
2019
Q1 | $3.43M | Buy |
14,090
+4,138
| +42% | +$1.09M | ﹤0.01% | 3250 |
|
|
2018
Q4 | $1.9M | Sell |
9,952
-1,279
| -11% | -$312K | ﹤0.01% | 3558 |
|
|
2018
Q3 | $3.68M | Sell |
11,231
-2,093
| -16% | -$641K | ﹤0.01% | 3197 |
|
|
2018
Q2 | $4.16M | Buy |
13,324
+3,840
| +40% | +$1.17M | ﹤0.01% | 3076 |
|
|
2018
Q1 | $2.31M | Buy |
9,484
+344
| +4% | +$96.5K | ﹤0.01% | 3493 |
|
|
2017
Q4 | $2.76M | Buy |
9,140
+746
| +9% | +$208K | ﹤0.01% | 3523 |
|
|
2017
Q3 | $2.22M | Buy |
8,394
+1,398
| +20% | +$404K | ﹤0.01% | 3885 |
|
|
2017
Q2 | $1.84M | Sell |
6,996
-702
| -9% | -$176K | ﹤0.01% | 3913 |
|
|
2017
Q1 | $2.77M | Buy |
7,698
+3,695
| +92% | +$1.14M | ﹤0.01% | 3437 |
|
|
2016
Q4 | $1.16M | Buy |
4,003
+1,146
| +40% | +$355K | ﹤0.01% | 4324 |
|
|
2016
Q3 | $973K | Buy |
2,857
+1,108
| +63% | +$405K | ﹤0.01% | 4427 |
|
|
2016
Q2 | $743K | Sell |
1,749
-729
| -29% | -$300K | ﹤0.01% | 4466 |
|
|
2016
Q1 | $793K | Sell |
2,478
-3,461
| -58% | -$1.18M | ﹤0.01% | 4291 |
|
|
2015
Q4 | $3.08M | Sell |
5,939
-3,436
| -37% | -$1.27M | ﹤0.01% | 3258 |
|
|
2015
Q3 | $2.75M | Buy |
9,375
+7,084
| +309% | +$2.52M | ﹤0.01% | 3457 |
|
|
2015
Q2 | $900K | Sell |
2,291
-1,247
| -35% | -$440K | ﹤0.01% | 4634 |
|
|
2015
Q1 | $1.07M | Buy |
3,538
+2,787
| +371% | +$680K | ﹤0.01% | 4397 |
|
|
2014
Q4 | $167K | Sell |
751
-7,913
| -91% | -$1.63M | ﹤0.01% | 6288 |
|
|
2014
Q3 | $2.01M | Buy |
8,664
+8,224
| +1,869% | +$2.07M | ﹤0.01% | 3925 |
|
|
2014
Q2 | $97K | Sell |
440
-4,146
| -90% | -$923K | ﹤0.01% | 6561 |
|
|
2014
Q1 | $1.45M | Buy |
4,586
+248
| +6% | +$79K | ﹤0.01% | 4305 |
|
|
2013
Q4 | $1.13M | Buy |
4,338
+2,933
| +209% | +$642K | ﹤0.01% | 4633 |
|
|
2013
Q3 | $206K | Sell |
1,405
-2,423
| -63% | -$293K | ﹤0.01% | 5850 |
|
|
2013
Q2 | $580K | Buy |
+3,828
| New | +$524K | ﹤0.01% | 4815 |
|
Other funds holding TXMD
RCMNY
E
GF
Goldman Sachs's TXMD Position: Q2 2022 in Review
Goldman Sachs sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 57,207 shares — an estimated $1.09M sold.
Goldman Sachs first reported a position in TXMD in Q2 2013 and held it in 36 quarters. The position peaked at $4.16M in Q2 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.
- Goldman Sachs reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
- Goldman Sachs sold 57,207 TherapeuticsMD shares in Q2 2022, an estimated $1.09M.
- Goldman Sachs first reported a position in TherapeuticsMD in Q2 2013 and held it in 36 quarters.
- Goldman Sachs's TherapeuticsMD position peaked at $4.16M in Q2 2018.
- 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.
Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.